Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... 24, 2014  Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... compared with the prior year. Reported sales increased 5% ... Net earnings per diluted share as reported (EPS) were ... 2013. Adjusted EPS was $2.57, an increase of 9% ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... (Nasdaq: BIOD ) today reported financial results for the ... Year 2011 Financial Results Biodel reported a net loss ... or $0.20 per share, compared to a net loss of $11.1 ... prior year. Research and development expenses were $5.5 ...
... CFN ), a leading, global medical technology company, ... Dec. 31, 2010. "Our strong second quarter results ... Infection Prevention businesses, and a benefit from a lower tax ... had announced in November 2010 his plans to retire. On ...
Cached Medicine Technology:Biodel Reports First Quarter Fiscal Year 2011 Financial Results 2Biodel Reports First Quarter Fiscal Year 2011 Financial Results 3Biodel Reports First Quarter Fiscal Year 2011 Financial Results 4Biodel Reports First Quarter Fiscal Year 2011 Financial Results 5Biodel Reports First Quarter Fiscal Year 2011 Financial Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 2CareFusion Reports Second Quarter Fiscal 2011 Results 3CareFusion Reports Second Quarter Fiscal 2011 Results 4CareFusion Reports Second Quarter Fiscal 2011 Results 5CareFusion Reports Second Quarter Fiscal 2011 Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 7CareFusion Reports Second Quarter Fiscal 2011 Results 8CareFusion Reports Second Quarter Fiscal 2011 Results 9CareFusion Reports Second Quarter Fiscal 2011 Results 10CareFusion Reports Second Quarter Fiscal 2011 Results 11CareFusion Reports Second Quarter Fiscal 2011 Results 12CareFusion Reports Second Quarter Fiscal 2011 Results 13CareFusion Reports Second Quarter Fiscal 2011 Results 14CareFusion Reports Second Quarter Fiscal 2011 Results 15
(Date:7/25/2014)... The report, "Wireless Gigabit (WiGig) Market ... Alliance, Access Points, Routers, Residential Gateways, Backhaul Equipment) ... Analysis (2014 - 2019)," provides a comprehensive market ... by WiGig enabled products, and regions. The report ... WiGig market, and provides the quantitative (market size ...
(Date:7/25/2014)... 2014 Garth Brooks Chicago tickets go ... Arena in Rosemont. Garth Brooks was one of the leaders ... first single in 1989. Since "Much Too Young (To Feel This ... from the Tulsa, Okl. native and in the years that he ... back on a stage and in the recording studio. Between 2001 ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... New York, New York (PRWEB) July 25, 2014 ... reviews JDRF’s revenue and spending during fiscal year 2013 (July ... government’s National Institutes of Health (NIH), the JDRF is the ... world. It has global reach and relationships with most ... better positioned to deliver a cure for type 1 diabetes ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Project Ninety ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , For more than four decades, Project ... Area community through its residential alcohol and substance abuse ... on Project Ninety's humble idea and how it has ...
Breaking Medicine News(10 mins):Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3
... ... a leading provider of information-based technology services to the health care industry, ... Texas in addition to its services that are provided to physicians throughout ... New Hampshire and is owned by Medical Protective, part of the Berkshire ...
... NJ A recent study published in International ... extract from the bark of the French maritime pine ... associated with various health problems. Dr. Raffaella Canali ... in Rome, Italy, found that Pycnogenol inhibits the generation ...
... , , PORTLAND, Ore., ... reform is the power of simple questions that people can ask each ... , To spark this effort, Regence BlueCross ... to inspire debate, discussion, and ultimately engagement and action by consumers. As ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... HARRISBURG, Pa., July 15 The Department of Environmental Protection and ... day for June 16 in the Philadelphia region. , ... will be code ORANGE for ozone in the region, which includes ... , The U.S. Environmental Protection Agency,s standardized ...
... , PITTSBURGH, Jul. 15 Leo W. Gerard, President ... to the U.S. House of Representatives, health care reform bill. , ... ) , , ... of efforts by the U.S. House leadership to fix our broken ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:Study demonstrates the anti-inflammatory properties of pine bark extract 2Health News:Regence Launches Effort to Further Health Care Debate 2Health News:Regence Launches Effort to Further Health Care Debate 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Air Quality Action Day Forecast for July 16 in Philadelphia Region 2Health News:Statement by USW President Leo W. Gerard on U.S. House Health Care Reform Bill 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: